Immuno-Oncology Summit – 2024 – Poster Presentation P26 […]
Archives: Publications
Deploying a CD45-Antibody Drug Conjugate for Allogeneic Hematopoietic Stem Cell Transplant in Non-Human Primates
ASTCT-EBMT – 2024 – Poster Presentation […]
Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML
ASGCT – 2024 – Poster Presentation 1775 […]
Uncovering Molecular and Functional Dynamics of Human Hematopoietic Stem Cells during In Vitro Culture for Cell Therapy Manufacturing
Keystone Symposia – 2024 – Poster Presentation 1040 […]
Trem-cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity During Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
Tandem Meetings – 2024 – Encore Poster Presentation 310 […]
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33ALLO) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation (Trial in Progress)
Tandem Meetings – 2024 – Encore Poster Presentation 293 […]
Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to target AML
Keystone Symposia – 2024 – Poster Presentation 2538 […]
Read More… from Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to target AML
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
The Impact of CD45-Antibody-Drug Conjugate Conditioning on Clonal Patterning Post HSPC Transplantation in Rhesus Macaques
ASH – 2023 – Poster Presentation […]